NDC 70573-099

Ryplazim

Plasminogen

Ryplazim is a Intravenous Injection, Powder, Lyophilized, For Solution in the Plasma Derivative category. It is labeled and distributed by Prometic Biotherapeutics, Inc.. The primary component is Plasminogen.

Product ID70573-099_39339cec-7a8a-4a87-829f-3b91f6698782
NDC70573-099
Product TypePlasma Derivative
Proprietary NameRyplazim
Generic NamePlasminogen
Dosage FormInjection, Powder, Lyophilized, For Solution
Route of AdministrationINTRAVENOUS
Marketing Start Date2021-06-04
Marketing CategoryBLA /
Application NumberBLA125659
Labeler NamePrometic Biotherapeutics, Inc.
Substance NamePLASMINOGEN
Active Ingredient Strength69 mg/1
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 70573-099-02

1 VIAL, GLASS in 1 CARTON (70573-099-02) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS (70573-099-01)
Marketing Start Date2021-06-04
NDC Exclude FlagN
Sample Package?N

Drug Details


Trademark Results [Ryplazim]

Mark Image

Registration | Serial
Company
Trademark
Application Date
RYPLAZIM
RYPLAZIM
87247928 5929628 Live/Registered
ProMetic BioTherapeutics, Inc.
2016-11-25

© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.